LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

Home・Akcijų sąrašas・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Atidarymo kaina

SektoriusSveikatos priežiūra

11.28 -5.21

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.28

Max

12.01

Pagrindiniai rodikliai
By Trading Economics
Pajamos	227M
Pardavimai	139M
P/E Sektoriaus vid.	4.506 49.701
Pelno marža	163.843
Darbuotojai	1,796
EBITDA	1.3M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+67.36% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.1B
Ankstesnė atidarymo kaina	16.49
Ankstesnė uždarymo kaina	11.28

Naujienos nuotaikos

By Acuity

10%

90%

8 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

14.24 / 14.78 Palaikymas ir pasipriešinimas

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-19 20:36; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

2026-05-19 23:47; UTC

Rinkos pokalbiai

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

2026-05-19 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Technical Recovery -- Market Talk

2026-05-19 23:28; UTC

Rinkos pokalbiai

Uždarbis

Global Forex and Fixed Income Roundup: Market Talk

2026-05-19 23:28; UTC

Rinkos pokalbiai

Uždarbis

F&P Healthcare's Outlook Key for Investors -- Market Talk

2026-05-19 23:10; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-19 23:10; UTC

Rinkos pokalbiai

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

2026-05-19 22:02; UTC

Uždarbis

ZTO Express (Cayman): Di Xu to Resign From Board

2026-05-19 22:01; UTC

Uždarbis

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

2026-05-19 22:01; UTC

Uždarbis

ZTO Express (Cayman) 1Q EPS 39c >ZTO

2026-05-19 22:00; UTC

Uždarbis

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

2026-05-19 21:37; UTC

Uždarbis

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

2026-05-19 21:31; UTC

Įsigijimai, susijungimai, perėmimai

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

2026-05-19 21:01; UTC

Uždarbis

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

2026-05-19 20:58; UTC

Uždarbis

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

2026-05-19 20:46; UTC

Karštos akcijos

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

2026-05-19 20:43; UTC

Rinkos pokalbiai

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

2026-05-19 20:34; UTC

Uždarbis

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

2026-05-19 20:32; UTC

Uždarbis

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

2026-05-19 20:32; UTC

Uždarbis

James Hardie Industries 4Q EPS 5c >JHX

2026-05-19 20:32; UTC

Uždarbis

James Hardie Industries 4Q Sales $1.4B >JHX

2026-05-19 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices to Buy Empower Semiconductor for $1.5B

2026-05-19 20:18; UTC

Rinkos pokalbiai

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

2026-05-19 20:13; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-19 20:13; UTC

Rinkos pokalbiai

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

2026-05-19 20:03; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

2026-05-19 20:03; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

2026-05-19 20:02; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

2026-05-19 20:02; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

2026-05-19 19:23; UTC

Rinkos pokalbiai

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

67.36% į viršų

12 mėnesių prognozė

Vidutinis 20 USD 67.36%

Aukščiausias 20 USD

Žemiausias 20 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Hutchison China MediTech Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

14.24 / 14.78Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

8 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.